US Pharma MarketingQ&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal
Akeso CEO Michelle Xia on ivonescimab Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy…
For Akeso CEO Michelle Xia, the intense spotlight on her company and its PD-1xVEGF bispecific ivonescimab still feels new, despite several years in the headlines as one of the industry's most closely watched drug programs.
...
Source: Endpoints News